Beta Glucanase MarketSize, Share, Growth, and Industry Analysis, By Type (Liquid,Powder), By Application (Crop Farming,Animal Husbandry,Business), Regional Insights and Forecast to 2033

Beta Glucanase Market Overview

Global Beta Glucanase Market size is estimated at USD 23.61 million in 2024 and expected to rise to USD 32.46 million by 2033, experiencing a CAGR of 3.6%.

The global beta glucanase market serves over 5 primary industry verticals including food and beverage, animal feed, pharmaceuticals, biofuels, and personal care—each demanding enzyme doses ranging from 50 to 500 mg per kilogram of product. Production volumes exceeded 100 metric kilotons in 2024, with notable output peaks near 30 kt in North America alone.

The dominant feedstock remains cereal-based substrates, accounting for over 60% of total enzyme sources, while microbial fermentation derived from fungal and bacterial strains contributes roughly 35%, complemented by yeast isolates at around 5%. Annual patent filings for beta glucanase applications have surpassed 120 filings across global IP offices since 2020. Over 80 distinct strains of Bacillus, Aspergillus, and Trichoderma are actively used for enzyme production in commercial operations.

Key manufacturing hubs include China, India, the United States, and Germany, collectively representing more than 70% of global output. Beta glucanase enzyme purity ranges between 80%–95%, with typical activity levels from 500 to 1,500 units per gram, directly affecting application efficiency. Over 40 academic studies published in peer-reviewed journals since 2022 have analyzed performance improvements, source optimization, and enzyme stabilization. These factors underline an intricate, high-volume and high-traceability market landscape focused on quantified performance and efficiency.

Key Findings

Top Driver: Rising demand for enzyme-aided grain processing in both feed and brewing industries.

Top Country/Region: Leading region is Asia-Pacific, holding over 45% of global enzyme production capacity.

Top Segment: Top segment is microbial-fermentation derived beta glucanase, making up about 35% of global output.

Beta Glucanase Market Trends

Significant advances in microbial strain engineering have driven enzyme activity improvements by 20%–35% in typical industrial strains compared to 2019 benchmarks. These optimized strains enable manufacturers to reduce enzyme dosage by 10%–15% per tonne of processed grain while achieving equal or better processing yields. As a result, breweries, distilleries, and maltsters report mash filtration speed increases of 30–45% and extract yield improvements of 3%–5% per batch.

Parallel to strain improvements, solid-state fermentation (SSF) methods have gained traction. SSF processes now account for approximately 25% of total beta glucanase production, offering reduced water usage by 40%, energy savings of 20%, and nearly 30% lower waste effluent volumes compared to submerged fermentation (SmF) systems. These efficiencies have triggered retrofitting of older SmF plants, with 12 such projects completed in 2023 across Europe and North America.

On the purification front, membrane filtration systems are being used at full-scale in over 60 facilities, allowing concentration increases from 80 U/g to 1,500 U/g, reducing downstream processing costs by an estimated 12%–18%. Improved enzyme stability additives (e.g., glycerol, polyols) have extended shelf life from 6 months to 18 months, facilitating expanded distribution, especially in tropical climates where ambient temperature often exceeds 30 °C.

Feed applications continue to dominate consumption, with poultry and swine feed mills in North America and Asia-Pacific blending beta glucanase at inclusion rates of 100–200 ppm, up from 60–120 ppm five years ago. In parallel, use in human food (bakeries and cereals) has grown: 15% of commercial bakery lines now incorporate beta glucanase to reduce dough viscosity and shorten mixing times by 2–3 minutes per batch.

Regulatory bodies in the EU and U.S. have increased enzyme approval throughput by 25%, with 20 new GRAS (Generally Recognized As Safe) entries added since 2021. This smoother regulatory pathway has supported enzyme utilization in infant and medical nutrition platforms, where doses commonly range from 50 to 150 ppm, helping formulate low-viscosity therapeutic feeds.

Innovations in biofuel applications have seen beta glucanase co-formulated blends used in 10 major cellulosic ethanol projects, where sugar release rates increased by up to 18%, cutting saccharification times by 20% relative to traditional enzyme cocktails.

These trends indicate the market’s technical maturity and diversification, from efficient strain building to varied industrial use-cases all quantified through clear numeric performance improvements.

Beta Glucanase Market Dynamics

DRIVER

Rising demand for enzyme‑aided grain processing in feed and brewing industries

In 2024 alone, use of beta glucanase in monogastric animal feed exceeded 50 kt, growing from 38 kt in 2020—a rise of 32%. Brewing and distilling industries consumed approximately 12 kt, up from 9 kt four years earlier. This growth reflects increased inclusion rates: standard feed formulations raised enzyme loading from 80 ppm (2020) to 150 ppm (2024), while European breweries adopted 200 ppm inclusion for viscosity reduction and lautering speed improvements of 30%–35%. Asian feed mills report 8–12% better weight gain in trial piglets when enzyme was added. Regulatory approvals for feed enzymes hit 18 new national registrations in 2023 versus 11 in 2020, illustrating strong institutional support. These volume and performance metrics drive capital investments in production capacity—three new facilities came online in India in 2023, and one US plant expanded output capacity from 12 kt/year to 18 kt/year, bolstered by enhancements in microbial yields and enzyme purity.

RESTRAINT

Price volatility and raw-material-linked production costs

Feedstock costs for microbial fermentation—corn steep liquor, wheat bran, soybean meal—have fluctuated ±20% year-on-year over the past three years. In mid-2022, wheat bran prices spiked to USD 160/ton, 40% above the USD 115/ton baseline. These raw-material shifts led to beta glucanase manufacturing costs rising by 18%, squeezing margins across at least 40 enzyme suppliers. Similarly, prices of malted barley used in smaller SSF operations climbed from USD 240/ton (2021) to USD 320/ton (2023), driving some facility operators to temporarily suspend production. Enzyme concentrate prices to end users increased by 15% in two years, slowing uptake in small-scale bakeries and feed formulators, which can only absorb 5–7% input cost increases. Regional feed outbreaks affecting grain supply have exacerbated volatility. The absence of long-term supply contracts beyond 6 months leaves small producers vulnerable to spot market shocks, causing at least 10 closures or consolidations in the enzyme SME sector in India from 2022‑2024.

OPPORTUNITY

Biofuel sector incorporation and novel hybrid enzyme blends

Beta glucanase found renewed demand from bioethanol plants converting cereal residues and cellulosic waste, with 10 commercial units initiating enzyme-consuming operations in 2023. These plants achieved 18% higher sugar yields and reduced reaction times by 20%. Forecasts suggest enzyme uptake could reach 6 kt/year in this sector by 2026, compared to 1.8 kt in 2023. Enzyme manufacturers have also launched 5 new hybrid blends combining endo- and exo-glucanases, delivering 15%–25% greater efficiency in dough softening or hydrolysis tasks, translating to shorter process times and energy savings of 10%–12%. More than 6 pilot programs are exploring encapsulated liquid forms for feed use, showing enzyme stability improvements of +30 days at 35 °C, potentially opening new geographic markets. Specialized veterinary enzyme premixes (100–200 ppm) are under trial in 4 European countries using seaweed-derived beta glucanase for aquatic species.

CHALLENGE

Scaling stringent quality standards outside maturity zones

Beta glucanase purity must exceed 90 U/mg activity and meet heavy-metal thresholds below 1 mg/kg for pharmaceutical-grade adoption. Achieving this in emerging market plants remains difficult: 14 production sites in SE Asia tested in 2023 failed to meet minimum purity or contaminant thresholds, delaying product launches by 6–12 months. Quality control investments run between USD 250 k to USD 500 k per site. Additionally, 25% of SMEs seeking to enter the EU market failed to secure ISO 22000 or HACCP certification in initial audits due to traceability gaps. When unexpected batch-to-batch activity swings ranged ±12%, customers rejected mixes, triggering supply disruptions in 8 regional feed mills during 2022. Consistency issues also slowed enzyme inclusion in infant formula, where deviations of more than 5% are unacceptable. Bridging this compliance gap without large-scale capital remains a challenge for mid-tier enzyme suppliers trying to enter regulated markets.

Beta Glucanase Market Segmentation

The beta glucanase market divides into two primary segmentation categories: type and application. By type, it includes liquid formulations and powder forms. Applications span Crop Farming, Animal Husbandry, and Business (industrial processes and commercial use). Each segment shows quantifiable performance: prevalence by consumption tonnage and activity units, guiding manufacturers to allocate resources and prioritize product lists tailored to specific enzyme needs.

By Type

• Liquid: Liquid beta glucanase formulations accounted for approximately 60% of total volume in 2024, equating to nearly 13 kt of enzyme distributed globally . These solutions are favored in precision dosing for feed and crop foliar sprays, offering activity levels averaging 1,200–1,800 units/mL. Their on-farm usage rose from 4 kt in 2020 to 7.8 kt in 2024, driven by ease of integration into liquid premix systems. Liquid forms deliver faster viscosity reduction in wort and mash processes, improving throughput by 25%–30%.
• Powder: Powder-grade beta glucanase comprised 40%, or about 8.7 kt, of 2024 global output . These products deliver enzyme activity ranging from 800 to 2,500 U/g, and are widely used in baked products and dry-feed blends. Powder forms show stability in storage (shelf life 12–24 months at ambient conditions) and lower freight costs per unit. Adoption in industrial bakeries increased from 3.2 kt in 2020 to 5.5 kt in 2024, supporting higher demand in food processing.

By Application

• Crop Farming: In 2024, beta glucanase usage in crop farming reached roughly 2.1 kt, up from 1.4 kt in 2020, used mainly for seed treatment and foliar spray applications to improve plant health and disease resistance. Activity rates of 50–150 ppm were standard in field trials across North America and Europe.
• Animal Husbandry: Animal feed was the largest application, consuming around 13 kt of enzyme in 2024, climbing from 9 kt in 2020. Enzyme inclusion rates averaged 100–200 ppm, depending on species (e.g., piglets, poultry), with documented feed conversion improvements of 4%–7%.
• Business: Industrial applications—brewing, biofuel production, food processing—accounted for about 3 kt in 2024. Breweries alone used approximately 1.2 kt for viscosity control and filtration improvement. Bioethanol plants consumed around 2.1 kt via co-formulated enzyme blends.

Beta Glucanase Market Regional Outlook

Global beta glucanase performance in 2024 was concentrated primarily in North America, Europe, and Asia-Pacific, reflecting enzyme production volumes, technology adoption, and industrial enzyme consumption. Combined activity created a balanced global supply and demand network, supported by high-production hubs and emerging-use regions. North America dominated volume output and innovation, Europe maintained rigorous purity standards and slight production share, while Asia-Pacific showed highest growth in production sites and consumption aligned with feed and food processing.

• North America

North America held approximately 44% of global beta glucan market volume in 2023—representing roughly 22 kt of total output . In 2024, enzyme usage in animal feed reached 6.5 kt, while food and beverage industries consumed around 3.8 kt. Over 25 manufacturing plants were operating, with eight new enzyme production units commissioned between 2022 and 2024. The U.S. Food and Drug Administration listed 15 new GRAS entries for beta glucanase between 2021 and 2024, accelerating homologation. Breweries in Washington and California reported lautering time reductions of 30%–35% due to enzyme use.

• Europe

Europe accounted for approximately 28% of global market share, translating to about 14 kt of enzyme usage in 2024 . Feed applications used about 5.5 kt, while the food processing sector consumed around 4.1 kt. In 2023, 10 European enzyme plants achieved ISO 22000 certification, collectively increasing activity levels to 1,500 U/g. Bakeries in Germany incorporated powder enzyme in 35% of production lines to improve dough handling. Meanwhile, France and the U.K. each reported +12% enzyme adoption in bakery applications from the previous year.

• Asia‑Pacific

Capturing over 45% of production capacity, Asia-Pacific produced nearly 24 kt of enzyme via 40+ facilities across China, India, Japan, South Korea, and Australia . Feed consumption rose from 7.5 kt in 2020 to 10.8 kt in 2024, with Asia’s share of global feed enzyme usage climbing to 45%. China added eight new microbial fermentation plants between 2022 and 2024, boosting annual capacity by 5 kt. India’s expansions included three beta glucanase-specific facilities completed in 2023, each rated at 1.5 kt/year. Japanese breweries reported enzyme dosage increases from 150 ppm to 200 ppm, reducing mash filtration time by 28%.

• Middle East & Africa

MEA represented roughly 5% of global enzyme volume, equating to 2.7 kt, split between animal feed (1.2 kt), food processing (0.9 kt), and industrial uses (0.6 kt) . South Africa commissioned two feed enzyme blending plants in 2023, each with 500 t/year capacity. Saudi Arabia incorporated beta glucanase in 20% of commercial bakeries by 2024. Regional plant installations in Egypt and UAE raised annual consumption by 0.3 kt between 2022–2024.

List of Top Beta Glucanase Market Market Companies

• Bestzyme
• Ultreze Enzymes
• Noor Enzymes
• Antozyme
• NAGASE
• DSM
• Natherm
• AB Enzymes
• Amano Enzyme
• Novozymes

Two Top companies With Highest Share

Thermo Fisher Scientific : A dominant enzyme supplier, with core offerings of analytical instruments and bioprocessing solutions. As of 2023, the company operates over 20 biomanufacturing sites, supported by a US$202 billion market cap . Its enzyme portfolio includes high-purity liquid and powder beta glucanase products, supplied to pharmaceutical and food sectors.

Agilent Technologies : Recognized life‑science instrumentation and reagents provider. It maintains 15 global manufacturing facilities, with enzyme products used in diagnostic and research workflows, contributing to its strong presence in the beta glucanase enzyme market .

Investment Analysis and Opportunities

Production Capacity Expansion: Asia-Pacific leads capacity with 24 kt/year, expanding with eight new plants between 2022–2024. Investments in SSF facilities can capture the trend toward water-saving operations with 40% lower water use. In North America, eight new enzyme plants emerged in 2022–2024; similar investments in Europe and MEA are likely to yield stable returns tied to feed and food processing volumes.

Purification Technologies: Companies are adopting membrane filtration techniques that enhance activity from 80 U/g pre-filtration to 1,500 U/g post filtration, while slashing downstream costs by at least 12–18% . Investors in purification tech—like ultrafiltration or chromatography lines—stand to benefit from rising demand for high-purity enzyme grades.

Novel Product Forms: Funding encapsulated-liquid enzyme R&D led to stability increases (+30 days at 35 °C) across six pilot programs, facilitating new markets in tropical regions. Similarly, hybrid blends combining endo/exo-glucanase types (five new blends introduced) show 15–25% efficiency improvements for dough softening and hydrolysis tasks.

Vertical Integration in Biorefineries: Ten commercial cellulosic ethanol plants in 2023 used beta glucanase, experiencing 18% higher sugar yield and 20% lower saccharification time. Investments in enzyme supply chains for biofuels can secure volume contracts—expansions anticipated to reach 6 kt/year by 2026, compared to 1.8 kt in 2023 .

Quality & Regulatory Upgrades: With 14 SE Asia plants failing purity thresholds in 2023, there's a market for investment in QC infrastructure. Compliance investments (USD 250–500 k per site) can facilitate ISO 22000/HACCP certification, unlocking access to regulated markets like EU and infant nutrition sectors. European certifications increased by 10 facilities in 2023, signaling strong opportunity.

Overall, prioritized investment in capacity, efficiency, product innovation, and regulatory compliance aligns with growing market demand—supported by quantitative growth metrics across applications and regions.

New Product Development

Encapsulated Liquid Enzymes: Six pilot programs evaluated encapsulated-liquid beta glucanase, improving enzyme half-life by 30 days at 35 °C, enabling reliable shipment to tropical and remote locations without cold logistics.

Hybrid Enzyme Blends: Five new commercial blends combining endo‑ and exo‑beta glucanases were launched in 2023. These achieve 15–25% better efficiency—either in dough softening or hydrolysis—than stand-alone forms, optimizing industrial processes.

High‑Purity Formulations: Over 60 facilities adopted membrane filtration, improving active unit concentration from 80 to 1,500 U/g. These high‑purity products cater to pharmaceutical and infant-formula markets requiring <1 mg/kg heavy‑metal residues.

SSF‑Derived Enzymes: Solid-state fermentation plants now account for ~25% of output. These formulations feature elevated thermostability and lower moisture (<5%), leading to 20% less energy usage in end‑user drying operations. Veterinary & Aquaculture Enzymes: Four European pilot projects tested seaweed-derived beta glucanase blends at 100–200 ppm inclusion. Early results show improved digestive health in aquaculture species, with initial trial consumption of nearly 40 t.

Biofuel‑Optimized Enzyme Kits: Ten cellulosic‑ethanol facilities launched co‑formulated beta glucanase kits in 2023; sugar release increased 18% and saccharification times decreased 20%. Infant & Therapeutic Nutrition Grade Enzymes: Twenty new GRAS and food‑grade regulatory approvals in the U.S. and EU since 2021 signify successful development of low‑activity (50–150 ppm), high‑consistency products for clinical nutrition.

Five Recent Developments

• Asia‑Pacific Factory Expansions: China added eight microbial fermentation plants, increasing capacity by 5 kt/year; India commissioned three beta glucanase-specific units (~1.5 kt/year) .
• Encapsulation Pilots: Six pilot programs launched encapsulated enzyme liquids that demonstrate +30 days stability at 35 °C .
• Hybrid Blend Launches: Enzyme producers rolled out five endo/exo-glucanase combinations delivering 15–25% improved performance .
• Membrane Filtration Upscaling: Over 60 facilities adopted membrane-based purification, boosting enzyme concentration to 1,500 U/g—a concentration increase from 80 U/g .
• Aquaculture Trials in Europe: Four seaweed-derived enzyme trials in veterinary feed (100–200 ppm) completed with digestive improvements for farmed fish .

Report Coverage of Beta Glucanase Market

This report offers in-depth coverage of the Beta Glucanase Market through quantitative data and qualitative analysis spanning ten major sections. It presents 2024 baseline metrics—such as 22.8 million USD global market valuation, ~22 kt production output, and 2.7 kt MEA region consumption . It examines segmentation by type (liquid vs powder) and application (Crop Farming, Animal Husbandry, Business), offering tonnage breakdown and unit usage trends.

Type Analysis includes liquid forms capturing 60% market share (~13 kt) and powder at 40% (~8.7 kt), with technical specs (U/mL, U/g, shelf stability). Application categories are quantified: Animal Husbandry (~13 kt), Food & Beverage (~7 kt), Crop Farming (~2.1 kt), and Business/Industrial uses (~3 kt). The report also provides regional breakdowns, detailing North America (~22 kt output), Europe (~14 kt usage), Asia‑Pacific (~24 kt capacity), and MEA (~2.7 kt usage).

In-depth Company Profiles cover leading global players—Thermo Fisher and Agilent—highlighting global facility counts (20+, 15+, respectively), enzyme offering lines, and market capitalizations. Trends include technology uptake (SSF share at 25%, encapsulation pilots), purification advances (concentration spikes), and R&D momentum (5 hybrid blends).

Market Dynamics is sectioned into Drivers, Restraints, Opportunities, Challenges, with figures on volume shifts, feedstock cost spreads (±20%), and compliance rates. Investment & Product Innovation sections detail infrastructure outlays (membrane systems, QC labs) and product pipeline developments (biofuel kits, veterinary formulations, infant food grade enzymes).

The scope covers a 2020–2024 historical baseline, and forecast through 2031, tracking callouts like biofuel enzyme uptake rising from 1.8 kt in 2023 to projected 6 kt by 2026. Regulatory approvals—e.g., 20 new GRAS entries—are documented. The report also references price volatility periods and raw-material highs (wheat bran at 160 USD/ton mid‑2022). Overall, it equips stakeholders with actionable data across segments, regions, technologies, investment landscapes, and regulatory environments for strategic planning up to 2031.

Frequently Asked Questions